《新股消息》武漢有機第三度申請來港上市
內地甲苯衍生品供應商武漢有機控股捲土重來,第三度申請在港上市。據初步上市文件顯示,公司去年收入26.77億元人民幣(下同),按年跌14.6%;溢利則跌78.6%至7,290.2萬元。
公司上市的獨家保薦人為交銀國際,料上市所得款項淨額擬用於建設主要著重生產甲苯氯化產品及衍生品的新生產設施以增加湖北新軒宏生產基地的產能;用作研發活動;用作銷售及營銷活動;用於營運資金及一般企業用途。
根據弗若斯特沙利文報告,按2022年的銷售收入計,集團是中國最大的苯甲酸、苯甲酸鈉及苯甲醇生產商,分別佔當年中國市場總收入的59.1%、37.3%及36%。於全球市場,公司於2022年在苯甲酸、苯甲酸鈉及苯甲醇生產商中位居第二,分別佔當年全球市場總收入的35.7%、21.8%及21.3%。
武漢有機控股曾於2022年6月及去年2月入表申請在港上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.